Venetoclax

Resumen

Alternativas con registro en Colombia

• Asparaginasa
• Hidroxicarbamida
• Mitotane · costo anual estimado $ 98.359.105
• Pegaspargasa
• Arsenico Trioxido · costo anual estimado $ 1.706.778.690
• Anagrelida · costo anual estimado $ 73.836.580
• Eribulina

Estudios clínicos principales

• Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
  Fase 3 · 2014 · 445 participantes · Hoffmann-La Roche · NCT02242942
• MURANO: A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymph
  Fase 3 · 2014 · 389 participantes · Hoffmann-La Roche · NCT02005471
• A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are I
  Fase 3 · 2017 · 211 participantes · AbbVie · NCT03069352
• AMPLIFY: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untrea
  Fase 3 · 2019 · 984 participantes · Acerta Pharma BV · NCT03836261

Enfermedades relacionadas

• Cáncer (todos)
• Leucemias
• Linfomas

Fuentes

• Etiqueta FDA (DailyMed): Venclexta
• EMA: Venclyxto